Current State – Innovita Research
Innovita Research scientist at work

Image credit: Innovita Research.

Presently, the company continues research and development activity on anti-aging medicine, immunotherapeutic approach for cancer treatment and regenerative medicine. Particularly, these R&D projects are performed:

  1. Xenogenic anticancer vaccine preclinical investigation in murine models.
  2. Cellular mitochondrial transfer technology, preclinical investigation in vitro and in murine models.
  3. Project “M”, mice lifespan prolongation with the use of cellular, subcellular and biopharmaceutical approach.

 

During many years of research activity, the company has developed a number of technologies to overcome disbalances of biological systems, preparing drugs from the own tissues and cells of the patient. Personalized approach to treat a disease is the main target in our technologies. The current activities of the company are presented as follows:

Technology Diseases Current state
Lifespan prolongation with the use of cellular, subcellular and biopharmaceutical approaches. Age-related diseases. In vitro and in vivo experimental studies.
Antitumor adoptive leukocyte immunotherapy. Melanoma; renal cancer; colorectal cancer; gastric cancer; brain cancer; prostate cancer; lung cancer; breast cancer; thyroid carcinoma; ovarian carcinoma; pancreas cancer. In vitro and in vivo experimental studies; clinical investigations.
Antibacterial adoptive leukocyte immunotherapy. Chronic cystitis; chronic maxillary sinusitis, chronic otitus. Clinical investigations.
Reparative adoptive leukocyte immunotherapy. Osteoarthritis; arthritis; osteomyelitis; atrophic scar (post acne); alopecia; trophic ulcer; and eczema. Clinical investigations.
Antitumor cellular vaccination. Melanoma; renal cancer; colorectal cancer; gastric cancer; brain cancer; prostate cancer; lung cancer; breast cancer; thyroid carcinoma; ovarian carcinoma; pancreas cancer. In vitro and in vivo experimental studies; clinical investigations.
T-cell immunotherapy (T-cell vaccination). Multiple sclerosis; rheumatoid arthritis; psoriasis; spondylitis deformans; autoimmune vasculitis. Clinical investigations.


Innovita Research holds these patents for its technologies:

  • Xenogenic normal tissue-derived vaccines for breaking the immune tolerance to tumor-associated, antigens.
    Seledtsov V.I., Darinskas A., Seledtsova G.V. Patent WO 2016046651 A1, 2016..

 

The company provides a number of products for scientific research purposes:

 

The company uses Good Laboratory Practice (GLP) certified system for research activity and Good Manufacturing Practice (GMP) certified entities for small-scale production of cellular products for preclinical investigations.

Innovita Research also offers high quality pre-clinical trials performance service of any kind of customer substance, device or technology.